Advertisements



Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Category: europeSource: fortuneApr 16th, 2018

Merck"s Keytruda meets main goal in pivotal lung cancer trial

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Category: topSource: reutersApr 9th, 2018

Merck"s Keytruda helps lung cancer patients live longer in trial

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

Category: topSource: reutersApr 9th, 2018

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates......»»

Category: blogSource: 247wallstApr 17th, 2018

Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets

The pairing of Keytruda and chemotherapy reduced risk of death for patients with advanced lung cancer by half, a significant improvement......»»

Category: topSource: marketwatchApr 16th, 2018

"We are going to have lung cancer patients living longer and better:" A new kind of cancer treatment is about to change how we treat the disease (MRK, BMS)

Wikimedia Commons New cancer treatments that harness the body's immune system are ready to go mainstream.  In data presente.....»»

Category: topSource: businessinsiderApr 16th, 2018

This Lung Cancer Drug Could Let Patients Forgo Chemo—And It’s Sending Merck’s Stock Soaring

Merck gained.....»»

Category: europeSource: fortuneApr 9th, 2018

AstraZeneca"s immunotherapy drug gets US FDA nod for lung cancer treatment

US FDA granted approval for expanded use of Imfinzi to treat non-small cell lung cancer patients.....»»

Category: topSource: business-standardFeb 17th, 2018

Early Keytruda Results Win Merck An Upgrade

Merck & Co., Inc. (NYSE: MRK) announced encouraging data Tuesday from a key study of patients with lung cancer. Latest .....»»

Category: blogSource: benzingaJan 16th, 2018

Roche drug cocktail doubles chance of halting lung cancer

Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented......»»

Category: topSource: foxnewsDec 7th, 2017

Roche win boosts case for adding chemo to cancer immunotherapy

Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients.....»»

Category: topSource: business-standardNov 20th, 2017

The Bull Thesis For Merck Is Evaporating

The bullish case for Merck & Co., Inc. (NYSE: MRK) has been "derailed" after the company signaled to investors last week a longer-than-expected delay in a key lung cancer trial for its Keytruda therapy. Latest Ratings for MRK DateFirmA.....»»

Category: blogSource: benzingaOct 30th, 2017

Merck shares fall deeper into red as European lung-cancer marketing application pulled

Merck & Co. shares fell in the extended session Friday after the drug maker said it was no longer pursuing market approval for a lung cancer drug in Europe. Merck shares declined 2.3% to $56.91 after hours, adding to a 6.1% drop during Friday'.....»»

Category: topSource: marketwatchOct 27th, 2017

AstraZeneca shares plunge 16% as lung cancer study fails

The two injectable immunotherapy drugs failed to help patients in an advanced lung cancer trial.....»»

Category: topSource: business-standardJul 27th, 2017

AstraZeneca lung cancer study fails in big setback for company

AstraZeneca's combination of two immunotherapy drugs, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday......»»

Category: topSource: foxnewsJul 27th, 2017

Merck Posts Another Advance In The Lucrative Lung Cancer Market

Merck Posts Another Advance In The Lucrative Lung Cancer Market.....»»

Category: topSource: seekingalphaApr 17th, 2018

New Drug Combinations Improve Survival in Lung Cancer

Combining expensive cancer immunotherapies with each other or with older drugs prolonged survival in lung cancer patients, two studies show. But the costs are high......»»

Category: smallbizSource: wsjApr 17th, 2018

Merck Tightens Its Grip on Lung Cancer, as Bristol Lags: Gadfly

Merck Tightens Its Grip on Lung Cancer, as Bristol Lags: Gadfly.....»»

Category: topSource: washpostApr 16th, 2018

Brainstorm Health: Merck’s Lung Cancer Triumph, COPD and Women, Trump on Drug Prices

Brainstorm Health Daily: April 16, 2018 Hello and happy Monday, readers! This is Sy. New study results released Monday continue to cement drug giant Merck’s status as the force to be r.....»»

Category: europeSource: fortuneApr 16th, 2018

Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

Category: topSource: moneycentralApr 16th, 2018

Merck shares rise after beating rivals" lung cancer results

In a fierce rivalry to prove cancer drug combinations work better for advanced.....»»

Category: topSource: marketwatchApr 16th, 2018